Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Immune System Diseases

Rare Diseases

Neoplasm Metastasis

Sclerosis

Multiple Sclerosis

Multiple Sclerosis, Chronic Progressive

Autoimmune Diseases

Demyelinating Autoimmune Diseases, CNS

Autoimmune Diseases of the Nervous System

Demyelinating Diseases

Neoplastic Processes

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Micronutrients

All Drugs and Chemicals

Hematinics

Pharmaceutical Solutions

Iron

Ferrosoferric Oxide

Parenteral Nutrition Solutions

Subjects will undergo MR imaging of the brain and cervical spine for pre- and post-administration of gadoteridol (0.2 mL/kg), then pre- and post-administration of ferumoxytol (4 mg/kg). Scans will be obtained over the course of two separate imaging visits.

Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.

Ferumoxytol infusion

Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).

Gadoteridol

3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol

MRI Brain and Cervical Spine

M. Mateo Paz Soldan, MD, PhD

This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.

Novel Imaging Markers in SPMS

Novel Imaging Markers of Innate Immune Activation in Secondary Progressive Multiple Sclerosis

Assess the safety and tolerability of ferumoxytol in Secondary Progressive MS cohort based on Adverse Events

University of Utah

Assistant Professor, Department of Neurology, Division of Neuroimmunology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Novel Imaging Markers in SPMS	NCT05357833	Secondary Progr... Multiple Sclero... Multiple Sclero...	Ferumoxytol inf... Gadoteridol MRI Brain and C...	35 Years - 65 Years	University of Utah
Novel Imaging Markers in SPMS	NCT05357833	Secondary Progr... Multiple Sclero... Multiple Sclero...	Ferumoxytol inf... Gadoteridol MRI Brain and C...	35 Years - 65 Years	University of Utah

Spots Global Cancer Trial Database for perilesional microglia